Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
BMS brings the buzz around late-stage readouts amid a so-so Q1
Bristol Myers Squibb (BMS) is generating investor excitement around upcoming Phase III readouts for its next-generation anticoagulant milvexian and schizophrenia medication Cobenfy, as the company prepares for impending patent expiries on existing blockbusters. Despite a modest 1% increase in Q1 revenue to $11.5 billion, driven by its growth portfolio, these late-stage pipeline assets are seen as critical for future growth into the 2030s. Milvexian, a potential successor to Eliquis, is currently in two Phase III trials, while Cobenfy, despite a slow initial market uptake, has multiple upcoming readouts for Alzheimer’s disease psychosis and other neurological conditions.